PT - JOURNAL ARTICLE AU - IRENA ROHR AU - ROBERT ZEILLINGER AU - MICHAELA HEINRICH AU - NICOLE CONCIN AU - IGNACE VERGOTE AU - MANI NASSIR AU - SVEN MAHNER AU - ELS VAN NIEUWENHUYSEN AU - FABIAN TRILLSCH AU - DAN CACSIRE-TONG AU - RADOSLAV CHEKEROV AU - JALID SEHOULI AU - ELENA I. BRAICU TI - Role of IGF-I in Primary Ovarian Cancer – A Study of the OVCAD European Consortium DP - 2016 Mar 01 TA - Anticancer Research PG - 1015--1022 VI - 36 IP - 3 4099 - http://ar.iiarjournals.org/content/36/3/1015.short 4100 - http://ar.iiarjournals.org/content/36/3/1015.full SO - Anticancer Res2016 Mar 01; 36 AB - Background/Aim: IGF-I (insulin growth factor 1) is crucially involved in cellular proliferation. Moreover, deregulation of IGF-I has been shown to be relevant in the carcinogenesis of various tumor entities. However, the impact of IGF-I in epithelial ovarian cancer (EOC) is unclear. In the present study, we investigated the predictive and prognostic role of circulatory IGF-I in primary EOC patients. Patients and Methods: In the FP6 European Project “OVCAD”, 275 consecutive primary EOC patients were enrolled. Patients were eligible if radical cytoreductive surgery and platinum-based chemotherapy were performed. Plasma IGF-I was detected using ELISA. Results: Increased plasma IGF-I levels were more frequently found in well-differentiated epithelial ovarian carcinoma (p=0.0047). A weak correlation was observed between IGF-I levels and CA-125 in patients with serous EOC (p=0.04). No association between IGF-I expression and other clinico-pathological parameters was observed. Conclusion: IGF-I is overexpressed in patients with well-differentiated EOC. Further studies are warranted to elucidate the role of IGF-I in this sub-group of patients.